TB10 | 10mg | Current wholesale price | High-quality peptide products | Purity 99% factory direct sale
TDS
Pharmaceutical Grade
99%
Hong Kong
customizable
10vials/box
2027-12-25
Tirzepatide,Retatrutide,Survodutide,GHK-CU,GLOW,KLOW
-
Product Description
-
Seller Information
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
TR10 TR20 SM10 SM20 RT10 RT20 PA20 CH20 0v20 CGL10 MAZ10 SUR10 10AD BP10 CD2 CMD10 RA10 ET10 IPA10 FTPP AR50 cu100 GMD2 DS10 NJ100 TB5 TB10 TSM5 TSM10 SMO5 IGF-1 AE5 IGD G210 G610 HK2 H10 GTT600 KS10 KP10 MS20 ML10 MT10 TA10 OT10 P41 SK10 XA10
Categories:
Research-
Class:
Chimeric peptidomimetic (fat-targeting vascular disruptor)
Status:Research compound — Not FDA approved, clinical development discontinued
Mechanism:A synthetic chimeric peptide composed of a fat-vascular-targeting cyclic peptide (CKGGRAKDC) linked via a GG spacer to a pro-apoptotic peptide (KLAKLAK)2. Adipotide selectively binds prohibitin in the vasculature of white adipose tissue, then delivers the pro-apoptotic domain to induce vascular disruption, causing fat tissue death. In primate studies (2011), it produced significant weight loss (~11%) but also caused renal toxicity, leading to development discontinuation.
Activity note:Adipotide is not a receptor agonist. It functions as a targeted vascular disruptor. Functional activity is measured by tissue-specific apoptosis, not traditional EC50.
Source:PubChem: Adipotide (CID 163360068); Kolonin MG, et al. Sci Transl Med. 2004;6(148):148ra16.DOI
References-
PubChem:Literature:
Sci Transl Med: Kolonin MG, et al. (2004) — Adipotide mechanism; ChemicalBook: Adipotide (CAS 859216-15-2)
Disclaimer:Adipotide is NOT FDA-approved or EMA-approved. It is a research compound only. Clinical development was discontinued due to renal toxicity observed in primate studies. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,Survodutide,GHK-CU,GLOW,KLOW
-
Location:
Building 1, Floor 2, No. 96 Banhe Road, Huangpu District, Guangzhou City, Room 2164
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
12
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA
"> -
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
Company Profile of Guangzhou Henghuang Trading Co., Ltd. 